-CEA (carcinoembryonic antigen) is a well-known tumor-associated antigen overexpressed in many colon cancers but also present at lower levels in normal tissues, particularly in the gastrointestinal tract. CAR-T cells targeting CEA have been developed and tested in earlyphase clinical trials. However, on-target, off-tumor toxicity, such as gastrointestinal inflammation, remains a significant concern. -HER2 is another potential target for CAR-T therapy in colon cancer, especially in cases where HER2 is overexpressed. HER2-targeted CAR-T cells have been tested, but again, the risk of damaging normal tissues that express HER2 limits their application. -EGFR is overexpressed in some colon cancers, making it a target for CAR-T therapy. EGFRtargeted CAR-T cells have been explored, but their use is complicated by the widespread expression of EGFR in normal epithelial tissues, leading to potential toxicities. -GUCY2C (guanylate cyclase C) is a more specific antigen for gastrointestinal malignancies, including colon cancer, and is not significantly expressed in extraintestinal tissues. CAR-T cells targeting GUCY2C have shown promise in preclinical models, with ongoing research aimed at optimizing their safety and efficacy. -Mesothelin is another antigen that has been explored as a target for CAR-T therapy in various solid tumors, including colon cancer. While it is not as widely expressed in normal tissues, its role in colon cancer remains under investigation. The continued co-occurrence of CAR-T with hematological malignancies such as MM and AML, exhibiting upward trends in terms of number of publications, are indicative of the persistent pursuit/development and potential of CAR-T for the treatment of liquid tumors. Their moderate average fold increase and relatively high number of publications indicates high degree of establishment as compared to the emergence of CAR-T in the context of colon cancer, a type of solid tumor, which perhaps representative of the increasing efforts to develop CAR-T for solid cancers.